BALTIMORE, Maryland, June 29, 2026
CraniUS Therapeutics has received an initial $1.1 million award through the National Institutes of Health (NIH) Blueprint MedTech Optimizer Program, with the opportunity to secure up to $4 million in total funding to accelerate development of its NeuroPASS™ skull-embedded drug delivery platform. The innovative neurotechnology platform is designed to bypass the blood-brain barrier (BBB) and enable direct, repeatable delivery of therapies into brain tissue for patients with recurrent glioblastoma (GBM). The funding will support engineering, manufacturing, preclinical, and regulatory activities required to prepare the investigational device for its first-in-human clinical study. By overcoming one of the most significant barriers in neurological medicine, NeuroPASS™ has the potential to transform the treatment of brain tumors and other central nervous system (CNS) disorders, opening new opportunities for precision therapies including biologics, gene therapies, cellular therapies, and other advanced medicines that require reliable access to the brain.
NeuroPASS™ Aims to Overcome the Blood-Brain Barrier Challenge
The blood-brain barrier remains one of the greatest obstacles in treating neurological diseases because it prevents many therapeutic agents from reaching effective concentrations within brain tissue. CraniUS Therapeutics’ NeuroPASS™ platform has been specifically engineered to address this challenge through a fully implantable, skull-embedded drug delivery system that delivers medicines directly into targeted brain regions while minimizing systemic exposure. The refillable implant is positioned within the skull and incorporates a concealed refill port, enabling repeated outpatient dosing without requiring multiple invasive surgical procedures.
This innovative approach is designed to establish a new category of chronic brain access technology, allowing clinicians to administer long-term therapies more efficiently while supporting continuous treatment strategies. Initially focused on recurrent glioblastoma, the platform has broader potential applications across neuro-oncology, neurodegenerative diseases, and other CNS disorders where effective drug delivery has historically limited therapeutic success.
NIH Blueprint MedTech Program Accelerates Clinical Development
Advertisement
The award was granted through the NIH Blueprint MedTech Program, an initiative funded by the National Institute of Neurological Disorders and Stroke (NINDS) and administered by the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The highly competitive program provides non-dilutive funding, technical expertise, regulatory guidance, and commercialization support to accelerate the development of innovative medical technologies addressing disorders of the nervous system. The initial $1.1 million award, with potential expansion to $4 million, will enable CraniUS Therapeutics to complete critical engineering optimization, manufacturing development, preclinical validation, and regulatory preparation necessary for clinical evaluation.
Company leadership emphasized that participation in the Blueprint MedTech Program also strengthens opportunities for future strategic partnerships while advancing one of the most promising technologies designed to overcome the long-standing challenge of therapeutic delivery across the blood-brain barrier. This support reflects increasing federal investment in next-generation neurotechnology platforms capable of improving treatment outcomes for patients with devastating neurological diseases.
Platform Supports Future Precision Therapies for CNS Disorders
Although recurrent glioblastoma serves as the initial clinical indication, NeuroPASS™ has been developed as a versatile delivery platform capable of supporting multiple therapeutic modalities across a broad range of neurological conditions. The implant is designed to facilitate repeated administration of biologics, gene therapies, cell therapies, RNA-based medicines, and other precision therapeutics that require direct access to the central nervous system. Current treatment options for recurrent glioblastoma remain limited, with median overall survival generally ranging between six and nine months, highlighting the urgent need for innovative technologies capable of improving therapeutic effectiveness.
By enabling long-term targeted drug delivery beyond the blood-brain barrier, NeuroPASS™ may significantly expand treatment possibilities for diseases previously constrained by inadequate drug penetration into the brain. As precision medicine and advanced neurotherapeutics continue to evolve, CraniUS Therapeutics’ innovative platform positions the company at the forefront of next-generation neurotechnology, potentially redefining how clinicians deliver complex therapies for brain cancer and numerous other CNS disorders.
Source: CraniUS Therapeutics Partners press release
